603229.SH
奥翔药业
SSE · Healthcare · Biotechnology · CN
CNY 7.94
−1.98%Margins
Gross margin
54.1%
EBITDA margin
27.0%
EBIT margin
13.9%
Net margin
13.6%
FCF margin
3.2%
4.6%
Return on equity
3.4%
Return on assets
3.9%
Return on invested capital
0.25x
Asset turnover
CNY 120.4M
Cash from operations
—
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026